Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Incidence of Infections Associated with the Use of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphomas

Amneh A Fares, Diana Martinez, Saba Musleh Ud Din, Robert Wilkinson, Julio C Chavez, Fernando Manuel Vargas Madueno, Jose Sandoval-Sus

Blood (2023) 142 (Supplement 1): 2329.

https://doi.org/10.1182/blood-2023-174415

Published: 2023

Journal Articles

Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)

Saurabh Dahiya, Jay Y. Spiegel, Dasom Lee, Turab Mohammed, Forat Lutfi, Anmol Goyal, Caroline Hana, Julio C Chavez, Filip Ionescu, Matthew J. Frank, Sushma Bharadwaj, Jose Sandoval-Sus, Amer M. Beitinjaneh, Lazaros J. Lekakis, Joseph P McGuirk, Frederick L. Locke, David B. Miklos, Michael D. Jain

Blood (2023) 142 (Supplement 1): 4876.

https://doi.org/10.1182/blood-2023-188918

Published: 2023

Journal Articles

Final Results of a Multicenter Pilot Study Evaluating Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Aggressive Adult T-Cell Leukemia/Lymphoma

Christopher Dittus, Matthew Weinstock, Jeffrey A. Barnes, Jose Sandoval-Sus, Natalie S. Grover, Anne Beaven, Xianming Tan, Areej El-Jawahri, Shayna R Sarosiek, John Mark Sloan

Blood (2023) 142 (Supplement 1): 1692.

https://doi.org/10.1182/blood-2023-173822

Published: 2023

Journal Articles

Limited Duration Loncastuximab Tesirine with Rituximab Induces High Complete Metabolic Response Rate in High-Risk Relapsed/Refractory Follicular Lymphoma - a Phase 2 Study

Juan Pablo Alderuccio, Alvaro J. Alencar, Jonathan H. Schatz, Russ Kuker, Georgio Pongas, Isildinha M. Reis, Jay Y. Spiegel, Laura Medina Andara, Lazaros J. Lekakis, Joseph S. Gyedu, Jose Sandoval-Sus, Amer M. Beitinjaneh, Nathalie Padron, Izidore S. Lossos, Joseph D. Rosenblatt, David S. Lessen, Craig H. Moskowitz

Blood (2023) 142 (Supplement 1): 984.

https://doi.org/10.1182/blood-2023-178825

Published: 2023

Journal Articles

Mortality and Prognostic Factors of Adult Patients with Acute Leukemia Admitted to the ICU: A Systematic Review

Paloma L Cabral, Jose Sandoval-Sus, Zhenmei Zang, Alice Gallo de Moraes

Blood (2023) 142 (Supplement 1): 5870.

https://doi.org/10.1182/blood-2023-187794

Published: 2023

Journal Articles

The Role of Prophylactic Chemotherapy for the Prevention of Central Nervous System Relapse in Patients with Large B Cell Lymphoma: A Meta-Analysis

Luis Juarez-Salcedo, Nicole Ianniello, Emily Coughlin, Julio C. Chavez, Jose Sandoval-Sus, Samir Dalia, Rahul Mhaskar

Blood (2022) 140 (Supplement 1): 3825–3826.

https://doi.org/10.1182/blood-2022-169008

Published: 2022

Journal Articles

Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)

Arnon P. Kater, J Christine Ye, Jose Sandoval-Sus, Mar Bellido, Jacob Haaber Christensen, Anthony R. Mato, Ann Janssens, Toshihiko Oki, Daniela Hoehn, Marcia Rios, Alexandra Kuznetsova, Rebecca Valentin, Herbert Eradat

Blood (2022) 140 (Supplement 1): 850–851.

https://doi.org/10.1182/blood-2022-158298

Published: 2022

Journal Articles

Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy

Blood (2022) 140 (Supplement 1): 10396–10398.

https://doi.org/10.1182/blood-2022-169689

Published: 2022

Journal Articles

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Blood (2022) 140 (Supplement 1): 3839–3841.

https://doi.org/10.1182/blood-2022-157105

Published: 2022

Journal Articles

Clinical Features and Survival According to Minimal Residual Disease in a Colombian Population Diagnosed with B-Cell Acute Lymphoblastic Leukemia

Angela María Peña, Sandra Vanesa Rios, Luis Antonio Salazar, Manuel Rosales, Sara Ines Jimenez, Katherinee Morales-Chacon, Carlos Alberto Orozco Oviedo, Carlos Andres Perez, Xueyi Chen, Santiago Grandas, Gabriela Vesga, Ana Maria Prada, Miguel Ochoa, Maria Luna-Gonzalez, Jose Sandoval-Sus, Claudia Lucia Sossa

Blood (2021) 138 (Supplement 1): 4459.

https://doi.org/10.1182/blood-2021-153874

Published: 2021

Journal Articles

Association between Sociodemographic, Clinical and Immunophenotypic Variables with Disease Relapse and Survival at 12 Months, in Patients with B-Cell Acute Lymphoblastic Leukemia Treated at a Colombian University Hospital

Luis Antonio Salazar, Sandra Vanesa Rios, Angela María Peña, Maria Luna-Gonzalez, Mario Andrés Arenas, Zayda Muentes, Jonathan Javier Diaz-Jurado, Manuel Rosales, Carlos Alberto Orozco Oviedo, Sara Ines Jimenez, Luisa Sanchez-Sossa, Katherinee Morales-Chacon, Carlos Andrés Pérez, Jose Sandoval-Sus, Claudia Lucia Sossa

Blood (2021) 138 (Supplement 1): 4380.

https://doi.org/10.1182/blood-2021-148883

Published: 2021

Journal Articles

Impact of Sociodemographic and Clinical Factors on the Survival of Patients with Acute Myeloid Leukemia: A Multicenter Experience in Colombia, on Behalf of Acho's Renehoc-Pethema Investigators

Claudia Lucia Sossa, Virginia Abello, Angela María Peña, Luis Antonio Salazar, Guillermo Quintero Vega, William Armando Mantilla Duran, Henry Idrobo, Jheremy Enrique Reyes Castellanos, Lina Gaviria, Carlos Daniel Bermudez Silva, Rigoberto Gomez, Mario Ernesto Correa, Paola Guerrero, Jose Sandoval-Sus, David Martínez-Cuadrón, Miguel A. Sanz, Pau Montesinos

Blood (2021) 138 (Supplement 1): 3374.

https://doi.org/10.1182/blood-2021-150930

Published: 2021

Journal Articles

Interim Results of a Multicenter Pilot Study Evaluating Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Aggressive Adult T-Cell Leukemia/Lymphoma

Christopher Dittus, Matthew J Weinstock, Jeffrey A Barnes, Jose Sandoval-Sus, Xianming Tan, Xinyi Zhang, Areej El-Jawahri, Shayna Sarosiek, John Mark Sloan

Blood (2021) 138 (Supplement 1): 1395.

https://doi.org/10.1182/blood-2021-144422

Published: 2021

Journal Articles

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers

Blood (2021) 138 (Supplement 1): 455.

https://doi.org/10.1182/blood-2021-144308

Published: 2021

Journal Articles

Clinical Features of Myelodisplastic Syndromes in a Colombian Population: Retrospective Analysis of Two Large Referral Centers

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-141306

Published: 2020

Journal Articles

Exclusion of Patients Living with Chronic Viral Infections and Underrepresentation of Ethnic Minorities in Diffuse Large B-Cell Lymphoma Clinical Trials

Stephanie Boisclair, MD, Richie Uba, PharmD, Amanda Brahim, PharmD, Fernando Vargas Madueno, MD, Julio C. Chavez, MD, Jose Sandoval-Sus, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-143226

Published: 2020

Journal Articles

Outcomes of Front-Line Therapy for Adult T Cell Leukemia/Lymphoma: A Pooled Analysis of Two Institutions

Jose Sandoval-Sus, MD, Franco Castillo Tokumori, MD, Ning Dong, MD, Stephanie Boisclair, MD, Amanda Brahim, PharmD, Damaal Walker, PharmD, Sanjay Bridgelall, MD, Ling Zhang, MD, Hayder Saeed, MD, Lubomir Sokol, MD PhD

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-140070

Published: 2020

Journal Articles

Survival in Patients Who Underwent HLA-Haploidentical Stem Cell Transplantation in Two Centers in Colombia

Lisbeth Ramirez, MD, Juan Manuel Herrera, MD, Angela María Peña, MD, Maria Luna-Gonzalez, Claudia Marcela Chalela, MD, Luis Antonio Salazar, MD, Sara Ines Jimenez, MD, Manuel Rosales, MD, Alvaro Guerrero, MD, Margarita Velasco, MD MSc, Robinson Pacheco, MD MSc, Jose Sandoval-Sus, MD, Claudia Lucia Sossa

Blood (2020) 136 (Supplement 1): 32.

https://doi.org/10.1182/blood-2020-141846

Published: 2020

Journal Articles

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Yehuda E. Deutsch, MD, Robert Wilkinson, PharmD, Amanda Brahim, PharmD, Stephanie Boisclair, MD, Jose Sandoval-Sus, MD, Annie Kuehnel, APRN, Terrence J Bradley, MD, Chetasi Talati, MD, Ellen Madarang, PharmD, Jillian Lykon, PharmD, Justin M. Watts, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Hugo F. Fernandez, MD

Blood (2019) 134 (Supplement_1): 3896.

https://doi.org/10.1182/blood-2019-129331

Published: 2019

Journal Articles

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Ariel F Grajales-Cruz, MD, Julio Chavez, Virginia Olivia Volpe, MD, Jose Sandoval-Sus, MD, Bijal Shah, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Shanel Fisher, Rajesh R Nair, PhD, Yun Seongseok, MD, Hayder Saeed, MD, Leidy Isenalumhe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 5484.

https://doi.org/10.1182/blood-2019-129260

Published: 2019

NARROW

Incidence of Infections Associated with the Use of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphomas

Second-Line Chimeric Antigen Receptor T Cell Therapy (CAR-T) As Standard of Care for Relapsed-Refractory Large B-Cell Lymphoma (LBCL)

Final Results of a Multicenter Pilot Study Evaluating Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Aggressive Adult T-Cell Leukemia/Lymphoma

Limited Duration Loncastuximab Tesirine with Rituximab Induces High Complete Metabolic Response Rate in High-Risk Relapsed/Refractory Follicular Lymphoma - a Phase 2 Study

Mortality and Prognostic Factors of Adult Patients with Acute Leukemia Admitted to the ICU: A Systematic Review

The Role of Prophylactic Chemotherapy for the Prevention of Central Nervous System Relapse in Patients with Large B Cell Lymphoma: A Meta-Analysis

Subcutaneous Epcoritamab in Patients with Richter's Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)

Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Clinical Features and Survival According to Minimal Residual Disease in a Colombian Population Diagnosed with B-Cell Acute Lymphoblastic Leukemia

Association between Sociodemographic, Clinical and Immunophenotypic Variables with Disease Relapse and Survival at 12 Months, in Patients with B-Cell Acute Lymphoblastic Leukemia Treated at a Colombian University Hospital

Impact of Sociodemographic and Clinical Factors on the Survival of Patients with Acute Myeloid Leukemia: A Multicenter Experience in Colombia, on Behalf of Acho's Renehoc-Pethema Investigators

Interim Results of a Multicenter Pilot Study Evaluating Brentuximab Vedotin with Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Aggressive Adult T-Cell Leukemia/Lymphoma

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers

Clinical Features of Myelodisplastic Syndromes in a Colombian Population: Retrospective Analysis of Two Large Referral Centers

Exclusion of Patients Living with Chronic Viral Infections and Underrepresentation of Ethnic Minorities in Diffuse Large B-Cell Lymphoma Clinical Trials

Outcomes of Front-Line Therapy for Adult T Cell Leukemia/Lymphoma: A Pooled Analysis of Two Institutions

Survival in Patients Who Underwent HLA-Haploidentical Stem Cell Transplantation in Two Centers in Colombia

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only